Kishnani, P., Tarnopolsky, M., Sivakumar, K., Roberts, M., Byrne, B., Goker-Alpan, O., … Boudes, P. (2013). A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease. In Molecular Genetics and Metabolism (Vol. 108, pp. S54–S54). Elsevier BV. https://doi.org/10.1016/j.ymgme.2012.11.131

Kishnani, Priya, Mark Tarnopolsky, Kumarswamy Sivakumar, Mark Roberts, Barry Byrne, Ozlem Goker-Alpan, Karl Guter, et al. “A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease.” In Molecular Genetics and Metabolism, 108:S54–S54. Elsevier BV, 2013. https://doi.org/10.1016/j.ymgme.2012.11.131.

Kishnani P, Tarnopolsky M, Sivakumar K, Roberts M, Byrne B, Goker-Alpan O, et al. A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease. In: Molecular Genetics and Metabolism. Elsevier BV; 2013. p. S54–S54.

Kishnani, Priya, et al. “A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease.” Molecular Genetics and Metabolism, vol. 108, no. 2, Elsevier BV, 2013, pp. S54–S54. Crossref, doi:10.1016/j.ymgme.2012.11.131.

Kishnani P, Tarnopolsky M, Sivakumar K, Roberts M, Byrne B, Goker-Alpan O, Guter K, Pervaiz MA, Dasouki M, Mozaffar T, Finanger E, Johnson F, Boudes P. A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease. Molecular Genetics and Metabolism. Elsevier BV; 2013. p. S54–S54.